Funding Opportunities

Foundations and Organizations

1. **Alliance for Regenerative Rehabilitation Research and Training** ($15,000-$65,000)
   Visit: http://www.ar3t.pitt.edu/pilot/pilot.html

   PILOT FUNDING: As a means to support creative, interdisciplinary researchers in expansion of their Regenerative Rehabilitation research, we have established the AR^{3}T Pilot Funding Program.

   This program encourages new collaborations between regenerative medicine and rehabilitative medicine researchers; and supports the development of novel Regenerative Rehabilitation paradigms with the potential to improve patient health outcomes. Funds are distributed to investigators either working independently or in collaboration with one of the AR^{3}T participating laboratories.

   The proposed project *must* include both a regenerative medicine component as well as a rehabilitative component.

   Now open! Initial submissions are due November 4, 2016. Access the online pilot application to apply.

2. **American Physiological Association – S&R Foundation Ryuji Ueno Award** ($30,000)
   Visit: http://www.the-aps.org/mm/awards/Other-APS-Awards/Early-Career-Professional#Ueno

   The Ryuji Ueno Award is given annually to an individual demonstrating outstanding promise based on his/her research in wound healing, tissue remodeling, organ regeneration, or stem cell biology. Relevant projects can include a range of topics in fundamental research; ranging from exploring the cellular and molecular physiology of these processes to the impact on organism physiology. Applications are accepted from APS members who hold an academic rank of assistant professor or higher, or a comparable position if the member is not affiliated with an academic institution.

3. **Bright Focus** ($150,000 - $160,000)
   Visit: http://www.brightfocus.org/grants/types-grants

   BrightFocus Foundation is at the forefront of brain and eye health, advancing early-stage, investigator-initiated research around the world. BrightFocus is one of America's leading supporters of basic scientific investigations to better understand and find cures for Alzheimer's disease, age-related macular degeneration, and glaucoma.

4. **Human Frontier Science Program** (up to $450,000)
   Visit: http://www.hfsp.org/funding/research-grants

   Research grants are provided for teams of scientists from different countries who wish to combine their expertise in innovative approaches to questions that could not be answered by individual laboratories. Two types of Research Grant are available: Young Investigators' Grants and Program Grants. The 2017 cycle is closed, but will begin again in March 2017. NOTE: Postdoctoral Fellowships are also available for early career scientists to broaden their research skills by moving into new areas of study while working in a new country.

5. **Juvenile Diabetes Research Foundation** (various amounts)
   Visit: http://grantcenter.jdrf.org/rfa/

   JDRF is focused on funding and catalyzing research that will lead to a cure of T1D, improving the quality of life and relieving the burden for people living with T1D, and preventing the disease (For more details, see Diabetes 2012; 61:30). JDRF's focus and funding spans from early exploratory research and preclinical proof-of-principle to proof-of-concept clinical trials through to ensuring regulatory approval and reimbursement across all stages of T1D, while addressing the breadth of challenges in the discovery, development, and delivery of drugs and devices to cure, better treat, and prevent T1D.

6. **Leukemia & Lymphoma Society** (various amounts)
   Visit: http://www.lls.org/grant-finder?src1=22051&src2=

   LLS investigators are outstanding scientists at the forefront of leukemia, lymphoma and myeloma research at centers throughout the world. We award academic grants for studies that range from basic blood cancer research to research that uses the latest tools of genomics.

   We're also dedicated to funding blood cancer research to help improve the quality of life for patients and their families with our projects studying long-term and late effects.

7. **National Blood Foundation (AABB)**($75,000)
   Visit: http://www.aabb.org/research/nbf/Pages/grantapplication.aspx

   NBF encourages innovation through early-career scientific research grants and strategic research and education grants. Both grant programs supplement AABB's mission to further develop transfusion medicine, cellular therapies and regenerative medicine science.

8. **Stem Cell Network** – Canadian researchers encouraged to work w/others outside Canada)
   Visit: http://stemcellnetwork.ca/funding/

   Over the next two years, ending March 31st, 2018 SCN will fund research and training needs through four strategic initiatives, specifically, three research funding programs and a training, outreach & workshop program. All research proposals will be peer reviewed to ensure quality and scientific rigour and funding results will be based on peer review.

9. Wellcome Trust (UK)

Visit: http://www.wellcome.ac.uk/funding/

The Wellcome Trust is a UK-based organization that funds research to improve human and animal health. The Wellcome Trust supports research conducted outside the UK where research develops international partnerships, or focuses on biomedical or clinical medicine in developing countries. For a complete list of grant scheme.

Deadline guide:

- Project and Programme Grant applications may be submitted at any time and will be considered at Funding Committee meetings, which are held four times per year.
- PhD studentships are available through individual research programmes. Recruitment begins in December for the following October.
- A range of fellowship options are offered. Submission of applications occurs at specific times on a yearly or twice yearly basis.

10. Foundation Fighting Blindness (up to $900,000 over 3 years)

Visit: https://harringtondiscovery.smartsimple.com/s_Login.jsp

Foundation Fighting Blindness and Harrington Discovery Institute have partnered to form **The National Center for Excellence in Fighting Blindness, a Gund-Harrington initiative**. This initiative is focused on accelerating the translation of research findings in inherited retinal degenerative diseases (IRD) with the ultimate goal of developing new therapies to prevent, treat or cure blindness.

- The Gund-Harrington Scholar Award provides funding for translational drug development and cell therapy along with non-financial project support to help bridge the gap between laboratory-based research and the clinic.
- Funding includes up to $900,000 over three years. Non-financial support will be provided by Harrington Discovery Institute's Innovation Support Center, a team of pharmaceutical experts. This support includes project management and experienced industry advice in all aspects of drug development, encompassing chemistry, formulation, toxicology, regulatory, intellectual property and business development.
- Selected projects must demonstrate a reasonable expectation that they can develop a lead product with strong potential for clinical and commercial application by the end of the three year funding period.
- Gund-Harrington Scholar Award projects should have the following characteristics:
    - Innovative science that addresses a significant opportunity leading to treatment or prevention of inherited retinal degenerative diseases (IRD).
    - The potential to be developed into a commercial product.
    - Development of a small molecule or biologic.
    - Diagnostics are only acceptable if linked to a therapeutic product.

Multi-disciplinary investigators outside the field of retinal disease are particularly encouraged to apply.

11. Pediatric Device Development Award Program

Visit: http://www.ctsi.umn.edu/consultations-and-services/translational-research-support/funding-programs/pediatric-device-development-award-program

The Pediatric Device Development Award Program, previously named the Pediatric Medical Device Translational Grant Program, supports the development of pediatric medical devices, with the ultimate goal of improving pediatric patient outcomes and quality of life through technology-driven medical solutions.

The program's partners, CTSI's Office of Discovery and Translation (ODAT)and the Pediatric Device Innovation Consortium (PDIC), will provide funded investigators with work strategy guidance, frequent feedback, and access to comprehensive internal and external services.

Applications are accepted on a continuous basis. Please complete theFunding Request Form and submit it along with supporting documentation to the Program Manager at fenl0003@umn.edu.

NIH & NSF

National Institutes of Health
Website

Many funding opportunities too many to mention: Below are two specific grants offered for stem cell research by NIH.

National Science Foundation
http://www.nsf.gov/funding/aboutfunding.jsp

The National Science Foundation funds research and education in most fields of science and engineering. It does this through grants, and cooperative agreements to more than 2,000 colleges, universities, K-12 school systems, businesses, informal science organizations and other research organizations throughout the United States. The Foundation accounts for about one-fourth of federal support to academic institutions for basic research. Too many to list here.

Funding Opportunities Details - PIVOT

1. **Differentiation and Integration of Stem Cells (Embryonic and Induced-Pluripotent) Into Developing or Damaged Tissues (R01)** ($500,000)
   Visit: http://grants.nih.gov/grants/guide/pa-files/PAR-13-094.html

   The primary focus of the FOA is to promote in vivo studies of stem cells in animal models and in humans (if applicable) to better understand how stem cells function within developing or damaged tissues.

2. **Differentiation and Integration of Stem Cells (Embryonic and Induced-Pluripotent) Into Developing or Damaged Tissues (R21)** ($275,000)
   Visit: http://grants.nih.gov/grants/guide/pa-files/PAR-13-095.html

   The primary focus of the FOA is to promote in vivo studies of stem cells in animal models and in humans (if applicable) to better understand how stem cells function within developing or damaged tissues.

3. **Innovator Awards for Early Career Investigators in Translational Stem Cell Research** ($300K USD per annum for up to five years)
   Visit: http://www.nyscf.org/grants/stem-cell-investigator-awards

   NYSCF is soliciting applications from early career investigators for Innovator awards to be used for exploring the basic biology and translational potential of stem cells. The goal of this initiative is to foster bold and innovative science with the potential to transform the field of stem cell research, and advance understanding and use of stem cells in the development of treatments for human disease. In addition to providing funding, NYSCF partners with investigators to advance and translate their research.

4. **KY Cha Award in Stem Cell Technology** ($20,000)
   Visit: http://www.asrm.org/KY_Cha_Award/

   This grant is awarded by ASRM and supported by an endowment from the Asia-Pacific Biomedical Research Foundation. The purpose of this award is to provide start-up funds to initiate an innovative research project in regenerative medicine and stem cell technology. A research project in which the applicant is the primary investigator is the essential core of the award.

5. **Improvement of Animal Models for Stem Cell-Based Regenerative Medicine (R21)** ($275,000)

   This FOA encourages Exploratory/Developmental Research grant (R21) applications from institutions and organizations proposing research aimed at characterizing animal stem cells and improving existing, and creating new, animal models for human disease conditions. The intent of this initiative is to facilitate the use of stem cell-based therapies for regenerative medicine. The initiative focuses on the following areas: 1) comparative analysis of animal and human stem cells to provide information for selection of the most predictive and informative model systems; 2) development of new technologies for stem cell characterization and transplantation; and 3) improvement of animal disease models for stem cell-based therapeutic applications.

6. **Improvement of Animal Models for Stem Cell-Based Regenerative Medicine (R01)** ($$ not specified)

   This FOA encourages Research Project Grant (R01) applications from institutions and organizations proposing research aimed at characterizing animal stem cells and improving existing, and creating new, animal models for human disease conditions. The intent of this initiative is to facilitate the use of stem cell-based therapies for regenerative medicine. The initiative focuses on the following areas: 1) comparative analysis of animal and human stem cells to provide information for selection of the most predictive and informative model systems; 2) development of new technologies for stem cell characterization and transplantation; and 3) improvement of animal disease models for stem cell-based therapeutic applications.

7. **Biotechnology and Biochemical Engineering (BBE)** ($300,000-$600,000)
   Visit: http://www.nsf.gov/funding/pgm_summ.jsp?pims_id=505334

   The BBE program supports fundamental engineering research that advances the understanding of cellular and biomolecular processes in engineering biology and eventually leads to the development of enabling technology for advanced manufacturing and/or applications in support of the biopharmaceutical, biotechnology, and bioenergy industries, or with applications in health or the environment.

   Major areas of interest in the program include:
   - Metabolic engineering and synthetic biology for bio-manufacturing - Quantitative systems biotechnology
   - Tissue engineering and stem cell culture technologies
   - Protein engineering & design
   - Single cell dynamics and modeling
   - Development of novel "omics" tools for biotechnology applications

8. **Stem Cells in Lupus Grant (Request for Applications [RFAs] for Basic, Clinical, and Translational Research on Stem Cells in Lupus)** ($135,000)
   Visit: http://www.lupus.org/research/request-for-applications

   In recent years, research on stem cells for lupus has been of increased interest. In particular, in the past decade, autologous, hematopoietic, and mesenchymal stem cell transplantation have been reported as a promising therapy to achieve treatment-free, long-term remission in people with lupus. However, this research is still in its infancy and further work is needed to clarify issues relevant to relapse, treatment-related toxicity, and the development of secondary autoimmune disorders in recipients of stem cells as a treatment for lupus. Thus, new stem cell-mediated therapeutic approaches are urgently needed for people with lupus, especially those with enhanced efficacy and less toxicity than current treatment standards.

   This award provides funds for studies whose outcomes will facilitate the development of large-scale studies that will help researchers elucidate the following issues:
   - The advancement of research on stem cells (adult or induced) or stem cell transplantation (autologous or allogenic) for lupus in humans or animals.
   - Further understanding of the role of stem cell (adult or induced) transplantation (autologous or allogenic) on the pathophysiology or treatment of lupus in humans or animals.

Other Opportunities

Breakthrough Prize – opportunity to nominate a colleague
https://breakthroughprize.org/Prize/2

In the fifty years between the discovery of the double helix and the decoding of the human genome, we have undergone a revolution in our understanding of life. Since then the rate of discoveries has accelerated, and this rapid progress looks set to continue.

Armed with new knowledge and new technologies, fields like genetics, molecular biology, oncology and neurology are now making real strides. Not just in describing how cells and organs function but in fighting some of the most deadly diseases.

The Breakthrough Prize in Life Sciences honors transformative advances toward understanding living systems and extending human life.

Funding for Graduate students, Post Docs and new Investigators/Faculty

1. **Boehringer Ingelheim Fonds – travel grants & MD/PhD Fellowships** (various amounts)
   Visit: https://www.bifonds.de/fellowships-grants/our-programmes.html

   In the PhD fellowship programme, we award long-term fellowships around the world, supporting some 120 outstanding junior researchers at the same time. The Travel Grants programme is geared to PhD and MD students as well as postdoctoral fellows to enable their participation in short-term practical trainings and scientific courses (e.g. summer or winter schools). In both programmes, the Boehringer Ingelheim Fonds supports Europeans working in Europe and overseas, as well as students from overseas working in Europe. In the MD fellowship programme, we grant fellowships to medical students studying in Germany to help them pursue an ambitious experimental research project in basic biomedical research in Europe or overseas.

2. **Eppendorf & Science Prize for Neurobiology** ($25,000)
   Visit: http://corporate.eppendorf.com/en/company/scientific-awards/global-award/

   The international Eppendorf & Science Prize for Neurobiology is awarded annually to one young scientist for the most outstanding neurobiological research based on methods of molecular and cell biology conducted by him/her during the past three years.

3. **Japan Society for the Promotion of Science -**
   Postdoctoral Fellowship for Overseas Researchers ($ subject to situation)
   Visit: https://www.jsps.go.jp/english/e-fellow/guideline_03.html

   Several kinds of fellowships provide opportunities for young and excellent postdoctoral researchers from other countries to conduct, under the guidance of their hosts, cooperative research with leading research groups in universities and other institutions in Japan.

4. **Springer Junior Investigator Award - NAVBO's Award for Junior Faculty** ($750)
   Visit: http://www.navbo.org/awards/springer-junior-investigator

   This award, supported by Springer, is presented by NAVBO to an independent investigator from academia, government, or industry that has submitted an abstract to one of the workshops presented at NAVBO's annual meeting, Vascular Biology 2016. The recipient will give a 30 minute presentation (including time for Q&A) at the annual meeting, during the Closing Session on Thursday, November 3, 2017.

5. **Stem Cell-Derived Blood Products for Therapeutic Use: Technology Improvement (R43/R44)** ($1,500,000)
   Visit: http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-15-030.html
   The primary objective of this funding opportunity announcement is to support the development of improved techniques and tools to enhance the production of clinically-relevant, functional stem cell-derived red blood cells or platelets in a more efficient and cost-effective manner. The research supported will develop and enhance technologies that enable the production of functional stem cell-based therapies with potential commercial and clinical viability.

6. **Early-Career Scientific Research Grants Program (NBF Scientific Research Grants Program)** ($75,000)

   Since its inception, the NBF has awarded over $8 million to early-career investigators through its Scientific Research Grants Program. NBF awards grants for investigator-initiated original research in all aspects of blood banking, transfusion medicine, cellular therapies and patient blood management. Many NBF early-career grant recipients have become leaders in the field.

   - Research content areas eligible for the grant program include the following:
     Hematology:
     - Autologous and allogeneic stem cell transplants
     - Detection of residual disease following stem cell transplants
   - Cellular Therapies:
     - Studies on mechanisms or roles of cells in stem cell transplantation
     - Studies on cytokines or growth factors involved in stem cell differentiation

7. **Young Investigator Award** (up to $250,000)
   Visit: http://www.acgtfoundation.org/grants-and-research/research-grants/

   The overall objectives of this grant are to advance cell and gene therapy into the causes, treatment and prevention of all types of cancer by promoting development of novel and innovative studies by young investigators. The emphasis of this initiative is to promote basic and pre-clinical research approaches utilizing cells and genes as medicine. ACGT will direct its grants into areas of cell and gene therapy research that have demonstrated great promise. The seven main areas of research ACGT will support are:
   1. Tumor-Specific Replicating Viruses and Bacteria
   2. Anti-angiogenesis
   3. Immune-modulatory Therapy and Cancer Vaccines
   4. Oncogene/Suppressor Oncogene/Apoptosis Directed Therapy
   5. Tumor Targeting and Vector Development
   6. Cancer Stem Cell Directed Therapy
   7. Other Gene/Cell based Therapies

Regenerative Medicine Minnesota

Visit: http://www.regenmedmn.org/apply-grant-rfps-updated-september-12

Proposals are due October 25, 2016

Regenerative Medicine Minnesota aims to improve the health of Minnesotans by advancing regenerative medicine research, education, industry and care delivery to patients. Requests for Proposals for the 2017-2018 Research Grants are now available. These grant applications (Discovery Science, Translational Research, and Clinical Trials) will be due October 25, 2016, and awards will be announced on January 30, 2017.

The grant application period for Education, Biotechnology/Biobusiness, and Clinical Care will open January 3, 2017, and be due February 14, 2017. These awards are scheduled to be announced on April 10, 2017.

1. **Discovery Science Grants - Proposals are due October 25, 2016**

Who can apply?

Applicants should be performing scientific and/or medical research in the state of Minnesota and must be at a rank of Assistant Professor or must have received a doctoral degree (MD, PhD, DO, or equivalent) within the past 12 years (June 1, 2004 or later) in a field pertinent to the award.If the applicant has more than one relevant doctoral degree, the date the most recent doctoral degree was obtained will be used to determine eligibility. Exceptions to the June 1, 2004 cutoff may be requested for investigators who had to spend time away from research related to medical concerns, disability, family care responsibilities, natural disasters, active duty military service, clinical training after the doctoral degree, or comparable factors. The NIH FAQs regarding these exceptions for Early Stage Investigators offer a guideline for the kinds of exceptions RMM will accept. Requests may be submitted with an application or, for prior approval, sent to regenmedmn@gmail.com.

What kind of research is being funded?

RMM seeks a diverse portfolio of research projects that focus on optimizing the body's own ability to heal. Relevant fields include cell and developmental biology, regenerative pharmacology and immunology, medicine and surgery, biotechnology, bioengineering, genetics, and other fields that develop ways to replace, restore, or regenerate damaged or malfunctioning cells, tissues, and organs to help people return to better health.

2. **Translational Research Grants - Proposals are due October 25, 2016**

Who can apply?

Applicants should be performing scientific and/or medical research in the state of Minnesota and must be at a rank of Assistant Professor or must have received a doctoral degree (MD, PhD, DO, or equivalent) within the past 12 years (June 1, 2004 or later) in a field pertinent to the award. If the applicant has more than one relevant doctoral degree, the date the most recent doctoral degree was obtained will be used to determine eligibility. Exceptions to the June 1, 2004 cutoff may be requested for investigators who had to spend time away from research related to medical concerns, disability, family care responsibilities, natural disasters, active duty military service, clinical training after the doctoral degree, or comparable factors. The NIH FAQs regarding these exceptions for Early Stage Investigators offer a guideline for the kinds of exceptions RMM will accept. Requests may be submitted with an application or, for prior approval, sent to regenmedmn@gmail.com.

What kind of research is being funded?

Funding is available for translational research that moves scientific discoveries into a potential clinical application by developing ways to replace, restore, or regenerate damaged or malfunctioning cells, tissues, and organs to help people return to better health.

3. **Clinical Trial Grants - Proposals are due October 25, 2016**

Who can apply?

Applicants (investigator, cooperative group, institution, network) must be qualified and capable of conducting the proposed study in compliance with the U.S. Food & Drug Administration's Good Clinical Practices and applicable Institutional Ethics Committees/Review Boards. The Principal Investigator (PI), who assumes sponsorship of the study, must comply with all applicable legal and regulatory requirements and must not be subject to any legal or regulatory restrictions or sanctions. Applicants should be performing scientific and/or medical research in the state of Minnesota and must be at a rank of Assistant Professor or must have received a doctoral degree (MD, PhD, DO, or equivalent) within the past 12 years (June 1, 2004 or later) in a field pertinent to the award. If the applicant has more than one relevant doctoral degree, the date the most recent doctoral degree was obtained will be used to determine eligibility. Exceptions to the June 1, 2004 cutoff may be requested for investigators who had to spend time away from research related to medical concerns, disability, family care responsibilities, natural disasters, active duty military service, clinical training after the doctoral degree, or comparable factors. The NIH FAQs regarding these exceptions for Early Stage Investigators offer a guideline for the kinds of exceptions RMM will accept. Requests may be submitted with an application or, for prior approval, sent to regenmedmn@gmail.com.